Shugaku Takeda, Ph.D. - Publications

Affiliations: 
2010 Biology & Biomedical Sciences (Developmental Biology) Washington University, Saint Louis, St. Louis, MO 
Area:
Human Development, Cell Biology, Molecular Biology

18 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2017 Wang GX, Tu HC, Dong Y, Skanderup AJ, Wang Y, Takeda S, Ganesan YT, Han S, Liu H, Hsieh JJ, Cheng EH. ΔNp63 Inhibits Oxidative Stress-Induced Cell Death, Including Ferroptosis, and Cooperates with the BCL-2 Family to Promote Clonogenic Survival. Cell Reports. 21: 2926-2939. PMID 29212036 DOI: 10.1016/J.Celrep.2017.11.030  0.32
2017 Nargund AM, Pham CG, Dong Y, Wang PI, Osmangeyoglu HU, Xie Y, Aras O, Han S, Oyama T, Takeda S, Ray CE, Dong Z, Berge M, Hakimi AA, Monette S, et al. The SWI/SNF Protein PBRM1 Restrains VHL-Loss-Driven Clear Cell Renal Cell Carcinoma. Cell Reports. 18: 2893-2906. PMID 28329682 DOI: 10.1016/J.Celrep.2017.02.074  0.32
2015 Chen HC, Kanai M, Inoue-Yamauchi A, Tu HC, Huang Y, Ren D, Kim H, Takeda S, Reyna DE, Chan PM, Ganesan YT, Liao CP, Gavathiotis E, Hsieh JJ, Cheng EH. An interconnected hierarchical model of cell death regulation by the BCL-2 family. Nature Cell Biology. PMID 26344567 DOI: 10.1038/Ncb3236  0.32
2015 Takeda S, Sasagawa S, Oyama T, Searleman AC, Westergard TD, Cheng EH, Hsieh JJ. Taspase1-dependent TFIIA cleavage coordinates head morphogenesis by limiting Cdkn2a locus transcription. The Journal of Clinical Investigation. 125: 1203-14. PMID 25664857 DOI: 10.1172/Jci77075  0.32
2014 Voss MH, Hakimi AA, Pham CG, Brannon AR, Chen YB, Cunha LF, Akin O, Liu H, Takeda S, Scott SN, Socci ND, Viale A, Schultz N, Sander C, Reuter VE, et al. Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 1955-64. PMID 24622468 DOI: 10.1158/1078-0432.CCR-13-2345  0.32
2013 Oyama T, Sasagawa S, Takeda S, Hess RA, Lieberman PM, Cheng EH, Hsieh JJ. Cleavage of TFIIA by Taspase1 activates TRF2-specified mammalian male germ cell programs. Developmental Cell. 27: 188-200. PMID 24176642 DOI: 10.1016/J.Devcel.2013.09.025  0.32
2013 Takeda S, Liu H, Sasagawa S, Dong Y, Trainor PA, Cheng EH, Hsieh JJ. HGF-MET signals via the MLL-ETS2 complex in hepatocellular carcinoma. The Journal of Clinical Investigation. 123: 3154-65. PMID 23934123 DOI: 10.1172/Jci65566  0.32
2013 Hakimi AA, Ostrovnaya I, Reva B, Schultz N, Chen YB, Gonen M, Liu H, Takeda S, Voss MH, Tickoo SK, Reuter VE, Russo P, Cheng EH, Sander C, Motzer RJ, et al. Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 3259-67. PMID 23620406 DOI: 10.1158/1078-0432.Ccr-12-3886  0.32
2013 Bean GR, Ganesan YT, Dong Y, Takeda S, Liu H, Chan PM, Huang Y, Chodosh LA, Zambetti GP, Hsieh JJ, Cheng EH. PUMA and BIM are required for oncogene inactivation-induced apoptosis. Science Signaling. 6: ra20. PMID 23532334 DOI: 10.1126/Scisignal.2003483  0.32
2013 Hakimi AA, Chen YB, Wren J, Gonen M, Abdel-Wahab O, Heguy A, Liu H, Takeda S, Tickoo SK, Reuter VE, Voss MH, Motzer RJ, Coleman JA, Cheng EH, Russo P, et al. Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma. European Urology. 63: 848-54. PMID 23036577 DOI: 10.1016/J.Eururo.2012.09.005  0.32
2013 Voss MH, Hakimi AA, Pham CG, Brannon AR, Chen Y, Cunha LF, Akin O, Liu H, Takeda S, Scott SN, Socci ND, Viale A, Schultz N, Sander C, Reuter VE, et al. Abstract 3515: Pathway convergent evolution underscores treatment response to MTOR inhibitors in kidney cancers. Cancer Research. 73: 3515-3515. DOI: 10.1158/1538-7445.Am2013-3515  0.32
2012 Chen DY, Takeda S, Oyama T, Hsieh JJ. "Targeting Taspase1 for Cancer Therapy"-Response. Cancer Research. 72: 2913. PMID 24619300 DOI: 10.1158/0008-5472.Can-12-1074  0.32
2012 Chen DY, Lee Y, Van Tine BA, Searleman AC, Westergard TD, Liu H, Tu HC, Takeda S, Dong Y, Piwnica-Worms DR, Oh KJ, Korsmeyer SJ, Hermone A, Gussio R, Shoemaker RH, et al. A pharmacologic inhibitor of the protease Taspase1 effectively inhibits breast and brain tumor growth. Cancer Research. 72: 736-46. PMID 22166309 DOI: 10.1158/0008-5472.Can-11-2584  0.32
2010 Liu H, Takeda S, Kumar R, Westergard TD, Brown EJ, Pandita TK, Cheng EH, Hsieh JJ. Phosphorylation of MLL by ATR is required for execution of mammalian S-phase checkpoint. Nature. 467: 343-6. PMID 20818375 DOI: 10.1038/Nature09350  0.32
2010 Chen DY, Liu H, Takeda S, Tu HC, Sasagawa S, Van Tine BA, Lu D, Cheng EH, Hsieh JJ. Taspase1 functions as a non-oncogene addiction protease that coordinates cancer cell proliferation and apoptosis. Cancer Research. 70: 5358-67. PMID 20516119 DOI: 10.1158/0008-5472.Can-10-0027  0.32
2008 Miles WO, Jaffray E, Campbell SG, Takeda S, Bayston LJ, Basu SP, Li M, Raftery LA, Ashe MP, Hay RT, Ashe HL. Medea SUMOylation restricts the signaling range of the Dpp morphogen in the Drosophila embryo. Genes & Development. 22: 2578-90. PMID 18794353 DOI: 10.1101/gad.494808  0.32
2008 Liu H, Takeda S, Cheng EH, Hsieh JJ. Biphasic MLL takes helm at cell cycle control: implications in human mixed lineage leukemia. Cell Cycle (Georgetown, Tex.). 7: 428-35. PMID 18235233 DOI: 10.4161/Cc.7.4.5426  0.32
2006 Takeda S, Chen DY, Westergard TD, Fisher JK, Rubens JA, Sasagawa S, Kan JT, Korsmeyer SJ, Cheng EH, Hsieh JJ. Proteolysis of MLL family proteins is essential for taspase1-orchestrated cell cycle progression. Genes & Development. 20: 2397-409. PMID 16951254 DOI: 10.1101/Gad.1449406  0.32
Show low-probability matches.